Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919970 | 1.00 | PTGS2 (0.46) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17810268 | 0.89 | PTGS2 (0.56) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6055209 | 0.86 | SLC6A3 (0.55) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7380604 | 0.85 | CYP3A4 (0.47) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11603975 | 0.85 | CYP3A4 (0.54) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23343729 | 0.84 | PTGS2 (0.44) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL3029503 | 0.84 | KDM4E (0.45) | MEN1KMT2AKDM4EUGT2B7LMNA | |
| SCHEMBL28621099 | 0.84 | CYP3A4 (0.50) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5375384 | 0.83 | MEN1 (0.44) | MEN1KMT2AKDM4EUGT2B7LMNA | |
| SCHEMBL598569 | 0.83 | CYP1A2 (0.45) | PTGS2CYP3A4CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1934159-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | PTGS2 2044/4885CYP3A4 71/4885CYP2D6 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.